Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of “Moderate Buy” by Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus rating of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $57.50.

COLL has been the subject of a number of research analyst reports. Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Needham & Company LLC restated a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th.

Collegium Pharmaceutical Stock Down 3.0%

COLL stock opened at $33.78 on Friday. The company’s 50 day moving average is $34.54 and its 200 day moving average is $41.58. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of 16.56 and a beta of 0.76. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical has a 1-year low of $28.34 and a 1-year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.24. The business had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. Collegium Pharmaceutical’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.49 earnings per share. Sell-side analysts predict that Collegium Pharmaceutical will post 6.38 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP David Dieter sold 13,976 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the sale, the executive vice president owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the transaction, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.85% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in COLL. Rubric Capital Management LP boosted its position in Collegium Pharmaceutical by 5.3% during the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after buying an additional 157,743 shares during the period. Vanguard Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after acquiring an additional 29,876 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Collegium Pharmaceutical by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after acquiring an additional 18,160 shares during the period. Janus Henderson Group PLC boosted its holdings in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after acquiring an additional 538,337 shares during the period. Finally, Principal Financial Group Inc. grew its position in Collegium Pharmaceutical by 0.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock worth $60,823,000 after acquiring an additional 3,891 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.